Advinus Bets On Novel Glucokinase, Claiming Advantages Over Peer Compounds As It Scans For Out-licensing Deal

MUMBAI - Past debacles in the glucokinase class of compounds notwithstanding, India's leading research firm Advinus Therapeutics has announced that it has discovered a novel molecule - coded GKM-001 - for the treatment of type 2 diabetes